A detailed history of Prelude Capital Management, LLC transactions in Novo Cure LTD stock. As of the latest transaction made, Prelude Capital Management, LLC holds 12,471 shares of NVCR stock, worth $224,727. This represents 0.02% of its overall portfolio holdings.

Number of Shares
12,471
Previous 31,487 60.39%
Holding current value
$224,727
Previous $492,000 56.71%
% of portfolio
0.02%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$11.83 - $24.05 $224,959 - $457,334
-19,016 Reduced 60.39%
12,471 $213,000
Q1 2024

May 15, 2024

BUY
$12.42 - $17.29 $391,068 - $544,410
31,487 New
31,487 $492,000
Q3 2021

Nov 15, 2021

SELL
$116.17 - $194.55 $162,289 - $271,786
-1,397 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$130.4 - $225.58 $16,039 - $27,746
-123 Reduced 8.09%
1,397 $310,000
Q1 2021

May 17, 2021

BUY
$124.11 - $190.17 $35,247 - $54,008
284 Added 22.98%
1,520 $201,000
Q2 2020

Aug 14, 2020

BUY
$57.2 - $74.41 $70,699 - $91,970
1,236 New
1,236 $73,000
Q2 2019

Aug 14, 2019

SELL
$42.22 - $63.23 $988,074 - $1.48 Million
-23,403 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$31.96 - $56.12 $57,911 - $101,689
-1,812 Reduced 7.19%
23,403 $1.13 Million
Q4 2018

Feb 14, 2019

SELL
$28.72 - $52.63 $33,142 - $60,735
-1,154 Reduced 4.38%
25,215 $844,000
Q3 2018

Nov 14, 2018

SELL
$32.0 - $52.4 $8,480 - $13,886
-265 Reduced 0.99%
26,369 $1.38 Million
Q2 2018

Aug 14, 2018

BUY
$19.85 - $32.0 $42,101 - $67,872
2,121 Added 8.65%
26,634 $834,000
Q1 2018

May 15, 2018

SELL
$19.3 - $23.65 $40,935 - $50,161
-2,121 Reduced 7.96%
24,513 $534,000
Q4 2017

Feb 14, 2018

BUY
$16.3 - $21.9 $279,919 - $376,088
17,173 Added 181.51%
26,634 $538,000
Q3 2017

Nov 14, 2017

BUY
$18.05 - $21.75 $170,771 - $205,776
9,461
9,461 $188,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.89B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.